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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Russian language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 100 JIA patients (25% systemic, 19% oligoarticular, 38% RF-negative polyarthritis, 18% 
other categories) and 198 healthy children, were enrolled in two centres. The JAMAR components discriminated healthy 
subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Russian 
version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical 
practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Russian parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Russian language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from January 2015 
to January 2017. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, and 3 = unable to do 
and not applicable if it was not possible to answer the 
question or the patient was unable to perform the task 
due to their young age or to reasons other than JIA. 
The total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to the international guidelines with 2–3 forward 
and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cultural 
adapted in a similar language (i.e. Spanish in South Ameri-
can countries), only the probe technique was performed. 
Reading comprehension and understanding of the translated 
questionnaires were tested in a probe sample of 10 JIA par-
ents and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption (mean and standard devia-
tion [SD] equivalence); the second Likert assumption or 
equal item–scale correlations (Pearson r: all items within 
a scale should contribute equally to the total score); third 
Likert assumption (item internal consistency or linear-
ity for which each item of a scale should be linearly 
related to the total score that is 90% of the items should 
have Pearson r ≥ 0.4); floor/ceiling effects (frequency of 
items at lower and higher extremes of the scales, respec-
tively); internal consistency, measured by the Cronbach’s 
alpha, interscale correlation (the correlation between two 
scales should be lower than their reliability coefficients, 
as measured by Cronbach’s alpha); test–retest reliability 
or intra-class correlation coefficient (reproducibility of 
the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR 
sub-scales with the six JIA core set variables, with the 
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addition of the parent assessment of disease activity and 
pain by the Spearman’s correlation coefficients (r) [17] 
and the discriminant validity, which assesses whether 
the JAMAR discriminates between the different JIA cat-
egories and healthy children [18]. Quantitative data were 
reported as medians with 1st and 3rd quartiles and cat-
egorical data as absolute frequencies and percentages.
The complete Russian parent and patient versions of 
the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Russian JAMAR was fully cross-culturally adapted 
from the standard English version with three forward and 
two backward translations with concordance in 117/123 
translation lines (95.1%) for the parent version and 
104/120 lines (86.7%) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range: 100–100%). All the 120 lines 
of the patient version of the JAMAR were understood 
by at least 80% of the children (median = 100%; range: 
100–100%). The parent and child versions of the Russian 
JAMAR were unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 198 healthy children (total 
of 298 subjects) were enrolled at two paediatric rheumatol-
ogy centres.
In the 100 JIA subjects, the JIA categories were 25% with 
systemic arthritis, 19% with oligoarthritis, 38% with RF-
negative polyarthritis, 3% with RF-positive polyarthritis and 
15% with enthesitis-related arthritis. Notably, none of the 
enrolled JIA patients is affected with psoriatic arthritis and 
with undifferentiated arthritis. (Table 1).
A total of 297/298 (99.7%) subjects had the parent ver-
sion of the JAMAR completed by a parent (100 from parents 
of JIA patients and 197 from parents of healthy children). 
The JAMAR was completed by 286/297 (96.3%) mothers 
and 11/297 (3.7%) fathers. The child version of the JAMAR 
was completed by 289/298 (97%) children age 5.0 or older. 
Also patients younger than 7 years old, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. “Results” 
refer mainly to the parent’s version findings, unless other-
wise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items 
except for items 6 and 8, whereas a reduced number of 
response choices were used for all the PF items except for 
items from 1 to 5, item 7, item 9 and item 13.
The mean and SD of the items within a scale were roughly 
equivalent for the PF and for the HRQoL items. The median 
number of items marked as not applicable was 1% (0–2%) 
for the PF and 2.5% (2–4%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 86% (81–92%) for the PF 
items, 69% (68–75%) for the HRQoL-PhH items, and 62% 
(57–66%) for the HRQoL-PsH items. The median ceiling 
effect was 1% (0–1%) for the PF items, 2% (2–3%) for 
the HRQoL-PhH items, and 1% (0–2%) for the HRQoL-
PsH items. The median floor effect was 17% for the pain 
VAS, 15% for the disease activity VAS and 14% for the 
well-being VAS. The median ceiling effect was 0% for the 
pain VAS, 1% for the disease activity VAS and 0% for the 
well-being VAS.
Equal item–scale correlations (second Likert 
assumption)
Pearson item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the 
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 100 JIA patients
Data related to the JAMAR refer to the 100 JIA patients and to the 197 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF − poly-
arthritis
RF + poly-
arthritis
Enthesitis-
related arthritis
All JIA patients Healthy
N = 25 N = 19 N = 38 N = 3 N = 15 N = 100 N = 198
Female 17 (68%) 13 (68.4%) 28 (73.7%) 3 (100%) 7 (46.7%) 68 (68%) 98 (49.5%)*
Age at visit 9.7 (5.5–13.8) 13.1 (10.9–15.2) 14.1 (10.3–16.2) 17.1 (16–17.9) 13.1 (9.5–16.2) 12.9 (9.6–16)* 10.4 (8.7–12.7)*
Age at onset 2.7 (2–5.8) 4 (3–6.2) 4.9 (2–7.2) 10 (9–14.7) 8.6 (3.9–10.7) 4.8 (2.2–7.4)*
Disease duration 4.5 (1.1–8.9) 8.1 (5.4–11.2) 9 (4.7–11.1) 7.9 (1.3–8.1) 4.7 (1.5–7.2) 7.4 (2.6–10.2)*
ESR 15 (7–22) 9 (9–15) 12.5 (8–19) (–) 11 (3–14) 12 (8–18)
MD VAS 
(0–10 cm)
1.5 (0.5–4) 1.5 (1–3) 3.3 (1–4.5) 1 (0.5–1.5) 1.5 (0.5–3) 2 (0.5–3.8)
No. of swollen 
joints
0 (0–1) 0 (0–2) 1.5 (0–4) 0 (0–1) 1 (0–2) 0 (0–3)
No. of joints 
with pain
0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
No. of joints 
with LOM
0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
No. of active 
joints
0 (0–2) 0 (0–2) 1.5 (0–4) 0 (0–1) 1 (0–2) 1 (0–3)
Active systemic 
features
1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
ANA status 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Uveitis 0 (0%) 1 (5.3%) 1 (2.6%) 0 (0%) 0 (0%) 2 (2%)
PF total score 0 (0–5) 0 (0–1) 1.5 (0–4) 0 (0–3) 1 (0–3) 0 (0–3.5) 0 (0–0)#
Pain VAS 1 (0–4) 1.5 (0.5–3.5) 2 (1–5) 1 (0–1.5) 1.5 (0.5–4) 1.5 (0.5–4) 0 (0–0)#
Disease activity 
VAS
1.5 (0.5–4) 1 (0.5–1.5) 2.8 (1–5) 1 (0–1) 1.5 (1–3.5) 1.5 (0.5–4)
Well-being VAS 1.5 (0.5–3.5) 2 (0.5–4) 2.8 (1–4) 0.5 (0–2) 1.5 (0.5–4) 2 (0.5–3.8)
HRQoL-PhH 2 (0–4) 0 (0–1) 1 (0–3) 0 (0–2) 1 (0–2) 1 (0–3) 0 (0–0)#
HRQoL-PsH 3 (0–5) 1 (0–3) 1.5 (0–3) 0 (0–4) 3 (1–3) 2 (0–3) 0 (0–1)#
HRQoL total 
score
5 (1–9) 3 (0–3) 3 (0–6) 2 (0–4) 3 (1–5) 3 (0–5) 0 (0–1)#
Pain/swell. in 
> 1 joint
7 (28%) 7 (36.8%) 22 (57.9%) 0 (0%) 9 (60%) 45 (45%)* 0 (0%)#
Morning stiff-
ness > 15 min
2 (8%) 0 (0%) 7 (18.4%) 0 (0%) 1 (6.7%) 10 (10%) 0 (0%)#
Subjective 
remission
9 (36%) 3 (15.8%) 18 (47.4%) 0 (0%) 4 (26.7%) 34 (34%)
In treatment 23 (92%) 19 (100%) 38 (100%) 3 (100%) 13 (86.7%) 96 (96%)
Reporting side 
effects
5/23 (21.7%) 1 (5.3%) 5 (13.2%) 0 (0%) 1/13 (7.7%) 12/96 (12.5%)
Taking medica-
tion regularly
22/23 (95.7%) 19 (100%) 36 (94.7%) 2 (66.7%) 13/13 (100%) 92/96 (95.8%)
With problems 
attending 
school
0 (0%) 0 (0%) 3/31 (9.7%) 0 (0%) 0 (0%) 3/75 (4%) 0 (0%)*
Satisfied with 
disease out-
come
23 (92%) 19 (100%) 33 (86.8%) 3 (100%) 14 (93.3%) 92 (92%)
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PF items, with the exception of item 15, and for 100% of the 
HRQoL items.
Items internal consistency (third Likert assumption)
Pearson item–scale correlations were ≥ 0.4 for 80% of items 
of the PF (except for PF items 11, 12 and 15) and 100% of 
items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.86 for PF-LL, 0.91 for PF-HW, and 
0.64 for PF-US. Cronbach’s alpha was 0.91 for HRQoL-PhH 
and 0.85 for HRQoL-PsH.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 100/297 Child N = 92/289
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 86.0% 85.9%
 HRQoL-PhH 69.0% 60.9%
 HRQoL-PsH 62.0% 64.1%
 Pain VAS 17.0% 40.2%
 Disease activity VAS 15.0% 32.6%
 Well-being VAS 14.0% 27.2%
Ceiling effect, median
 PF 1.0% 1.1%
 HRQoL-PhH 2.0% 3.3%
 HRQoL-PsH 1.0% 3.3%
 Pain VAS 0.0% 1.1%
 Disease activity VAS 1.0% 0.0%
 Well-being VAS 0.0% 1.1%
Items with equivalent item–scale correlation 93% for PF, 100% for HRQoL 100% for PF, 90% for HRQoL
Items with item–scale correlation ≥ 0.4 80% for PF, 100% for HRQoL 100% for PF, 90% for HRQoL
Cronbach’s alpha
 PF-LL 0.86 0.81
 PF-HW 0.91 0.82
 PF-US 0.64 0.74
 HRQoL-PhH 0.91 0.79
 HRQoL-PsH 0.85 0.82
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 1.0 0.77
 HRQoL-PhH 0.94 0.74
 HRQoL-PsH 0.96 0.84
Spearman correlation with JIA core set variables, median
 PF 0.5 0.5
 HRQoL-PhH 0.2 0.5
 HRQoL-PsH 0.3 0.4
 Pain VAS 0.3 0.4
 Disease activity VAS 0.5 0.6
 Well-being VAS 0.4 0.4
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Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 5 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 9 days (range 8–10 days). The intraclass cor-
relation coefficients (ICC) for the PF total score showed an 
almost perfect reproducibility (ICC = 1). The ICC for the 
HRQoL-PhH and the ICC for the HRQoL-PsH showed an 
almost perfect reproducibility (ICC = 0.94 and ICC = 0.96, 
respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.2 to 
0.6 (median = 0.5). The PF total score best correlation 
was observed with the number of active joints (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.2 to 0.3 (median = 0.2), whereas for the PsH ranged 
from 0.1 to 0.3 (median = 0.3). The HRQoL-PhH and the 
HRQoL-PsH showed the best correlation with the parent’s 
assessment of well-being (r = 0.5, p < 0.001 for both).
The median correlations between the pain VAS, the well-
being VAS, and the disease activity VAS and the physician-
centred and laboratory measures were 0.3 (0.1–0.5), 0.5 
(0.2–0.6), 0.4 (0.3–0.5), respectively.
Discussion
In this study, the Russian version of the JAMAR was 
cross-culturally adapted from the original standard Eng-
lish version with three forward and two backward transla-
tions. According to the results of the validation analysis, 
the Russian parent and patient versions of the JAMAR 
possess satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated 
well between patients with JIA and healthy controls.
Psychometric performances were good for all domains of 
the JAMAR with few exceptions: three PF items (“Stretch 
out arms”, “Put hands behind neck” and “Bite into a sand-
wich or an apple”) showed a lower items internal consist-
ency. However, the overall internal consistency was good 
for all the domains, except for PF-US that is questionable.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from week to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, which 
suggests that children are equally reliable proxy reporters of 
their disease and health status as their parents. The JAMAR 
is aimed to evaluate the side effects of medications and 
school attendance, which are other dimensions of daily life 
that were not previously considered by other HRQoL tools. 
This may provide useful information for intervention and 
follow-up in health care. In conclusion, the Russian version 
of the JAMAR was found to have satisfactory psychometric 
properties and it is, thus, a reliable and valid tool for the 
multidimensional assessment of children with JIA.
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